Rapamycin for longevity: what human trials show

Almost everything written about rapamycin rests on one sentence: it extends lifespan in mice. The sentence is true, and the study behind it is better than most. What follows it — that it therefore extends lifespan in people — has not been tested, and the human trials that exist were not built to test it.

This is the gap worth understanding, because it is where the claim is made and where it is never examined.

What the mouse study showed

In 2009, Harrison and colleagues published a result in Nature that has anchored the field since. Mice given rapamycin starting at 600 days of age — late in a mouse life, roughly the equivalent of starting in a person’s sixties — lived longer than controls. Measured by the age at which 90 percent of the animals had died, the increase was 14 percent in females and 9 percent in males.

Two features of the study matter more than the headline number.

The first is that the effect appeared at three independent test sites, in mice deliberately bred to be genetically mixed. That design exists to rule out the two most common explanations for a promising animal result: that it is a quirk of one inbred strain, or of one laboratory’s conditions. It ruled both out.

The second is that the authors were explicit about not knowing the mechanism. Rapamycin, they wrote, may extend lifespan by postponing death from cancer, by slowing mechanisms of aging, or both. Fifteen years later that question is still open, and it matters: a drug that delays one common cause of death in mice is a different proposition from a drug that slows aging itself.

The programme that produced this result, the National Institute on Aging’s Interventions Testing Program, is also worth knowing about for scale. Its 2017 update reported 53 lifespan experiments involving 30 candidate agents over eleven years, with significant effects on longevity published for six of them. Rapamycin is one of the six.

What the human trial measured

The longest published trial of rapamycin in healthy people is PEARL, reported in the journal Aging in 2025. It is a proper randomized controlled trial: 48 weeks, decentralised, double-blinded, placebo-controlled, with participants receiving placebo, 5 mg or 10 mg of compounded rapamycin weekly.

Its primary outcome was visceral fat, measured by DXA scan. Secondary outcomes were blood biomarkers, lean tissue mass and bone mineral content, with established surveys used for health and well-being.

The primary outcome did not change. Visceral fat in the treated groups was statistically indistinguishable from placebo, at p = 0.942 — about as flat a result as a trial can report.

This is the part that most coverage omits, and it is the most informative single fact about the trial. A trial’s primary outcome is the question it was designed to answer, chosen before the data existed. PEARL asked whether weekly low-dose rapamycin reduces visceral fat over a year, and the answer was no.

What it did find

Several other measures moved, and describing them accurately requires distinguishing them from the primary result.

Adverse events and serious adverse events were similar across all groups, and changes in blood biomarkers stayed within normal ranges. For a drug whose approved use is suppressing the immune system, a year at low intermittent doses without an excess of adverse events is a genuine and useful finding. Safety was, in effect, the question the trial answered best.

Among the secondary measures, lean tissue mass improved in women taking 10 mg (p = 0.013), as did self-reported pain in the same group (p = 0.015). Self-reported emotional well-being (p = 0.023) and general health (p = 0.004) improved among those taking 5 mg.

These are real numbers from a real trial, and they are also exactly the kind of finding that requires care. They are secondary outcomes, some of them confined to one sex and one dose, and several are self-reported. A trial that measures many things will find some of them moving. That is why the primary outcome is named in advance — and why a paper reporting a null primary result and positive secondary ones is best read as a reason to run the next trial, not as an answer.

What the trial could not measure

Nothing in PEARL bears on lifespan, and nothing could have. Forty-eight weeks is long enough to see side effects appear and far too short for survival to be an outcome. Every measure in the trial is a surrogate endpoint: a stand-in chosen because the thing people care about cannot be measured in the time available.

That limit is not a criticism of the trial, which is clear about what it did. It is a limit on the sentence “rapamycin is proven to work”, which no trial in healthy humans currently supports.

A 2025 review in the same journal put it directly. Examining the evidence for low-dose rapamycin and related compounds in healthy adults, its authors concluded that despite the preclinical evidence, the human data have yet to establish that rapamycin or its analogues is a proven therapy that can delay aging in healthy older adults, and that larger cohorts are needed.

What is known about people already taking it

Some doctors prescribe sirolimus off-label for healthspan, and that population has been surveyed rather than trialled.

A 2023 report in GeroScience collected data from 333 adults with a history of off-label rapamycin use, alongside 172 adults who had never used it, and presented initial evidence that the drug can be used safely in adults of normal health status. A follow-up analysis published in 2024 examined a specific signal from that cohort: about 26 percent of rapamycin users reported changes in oral health, most commonly mouth sores. The follow-up found, contrary to what the authors expected, that length of use, dose and dosing interval were not related to the incidence of mouth ulcers.

The value of these reports is in what they are, and the limit is the same thing. They describe people who chose the drug, compared with people who did not. Whatever separates those two groups — income, health anxiety, access to a sympathetic doctor, baseline health — separates the results too. This is the difference between a survey and a trial, and no amount of careful analysis closes it.

Where the evidence stands

Question	What exists	What it supports
Does it extend lifespan in mice?	Nature 2009, three sites, genetically mixed mice	Yes: +14 percent in females, +9 percent in males at 90 percent mortality
Does it extend lifespan in humans?	No trial has measured it	Nothing
Is it tolerated by healthy adults?	PEARL, 48 weeks, randomised, placebo-controlled	Adverse events similar to placebo over one year
Does it reduce visceral fat?	PEARL primary outcome	No: p = 0.942
Does it improve healthspan measures?	PEARL secondary and subgroup outcomes	Some measures moved; not what the trial was designed to answer
Is off-label use safe in practice?	Surveys of 333 users, 2023 and 2024	No signal of serious harm; about 26 percent reported oral health changes

The honest summary is short. In mice, rapamycin is among the best-replicated life-extending compounds known. In humans, it has been shown to be tolerable for a year at low weekly doses, and has not been shown to do anything else.